Results 21 to 30 of about 3,679 (147)

Initial therapeutic target attainment of perampanel in pediatric patients with epilepsy

Frontiers in Pharmacology, 2023
Perampanel is a promising option for the treatment of pediatric epilepsy, but its plasma concentration varies among patients. This retrospective study aimed to investigate the initial target attainment of perampanel plasma concentration in pediatric ...
Lingyan Yu, Meng Chen, Jieqiong Liu, Zhenwei Yu, Jianhua Feng, Haibin Dai   +5 more
doaj   +1 more source

Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies

Epilepsy and Behavior Case Reports, 2018
Perampanel, a selective, non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is approved for adjunctive treatment of focal seizures, with or without secondarily generalized seizures, and for primary ...
Patrick Kwan, Scott Mintzer, Antonio Laurenza, Anna Patten, Karen Cartwright   +4 more
doaj   +1 more source

Perampanel in real‐world clinical care of patients with epilepsy: Interim analysis of a phase IV study

Epilepsia Open, 2021
Objective To assess the retention rate, efficacy, safety, and dosing of perampanel administered to patients with epilepsy during routine clinical care in the retrospective phase IV, PROVE Study (NCT03208660).
James Wheless, Robert T. Wechsler, Marcelo Lancman, Sami Aboumatar, Anna Patten, Manoj Malhotra   +5 more
doaj   +1 more source

Patient-Reported Outcome Measures in Adult Patients Diagnosed with Epilepsy Being Treated with Perampanel

Patient Related Outcome Measures, 2022
Brian D Moseley,1 Shaloo Gupta,2 Nate Way,2 Jonathon Wright,2 John C Rowland,2 Victoria E Barghout,3 Feride Frech,4 Craig Plauschinat4 1Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH, 45267, USA; 2Real World
Moseley BD, Gupta S, Way N, Wright J, Rowland JC, Barghout VE, Frech F, Plauschinat C   +7 more
doaj  

Synergistic effect of perampanel with temozolomide on glioblastoma cells in vivo

Heliyon
The anti-epileptic drug perampanel, an α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor antagonist, exhibits anti-tumor effects against glioblastoma cells in vitro.
Takuma Nishide, Shun Yamamuro, Emiko Sano, Yumi Aida, Kaoru Nara, Genki Yazawa, Yoshinari Ozawa, Atsuo Yoshino   +7 more
doaj   +1 more source

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM

Фармакоэкономика, 2017
Perampanel (PER) is a novel drug for treatment of refractory partial epilepsy in patients≥12 y.o. with proven efficacy and safety. PER is registered and may also be used successfully as adjunctive treatment in therapy of primary generalized tonic-clonic ...
N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova   +4 more
doaj   +1 more source

Preliminary Asian experience of using perampanel in clinical practice

Biomedical Journal, 2017
Background: To analyze the efficacy and safety of perampanel over a 3-month period in a sample of Asian people with epilepsy. Methods: The efficacy and safety of perampanel as an adjunctive therapy for patients with epilepsy were retrospectively reviewed
Hsing-I Chiang, Siew-Na Lim, Hsiang-Yao Hsieh, Mei-Yun Cheng, Chun-Wei Chang, Wei-En Johnny Tseng, Han-Tao Li, Chin-Yin Lin, Tony Wu   +8 more
doaj   +1 more source

Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons. [PDF]

PLoS ONE, 2014
Perampanel is an aryl substituted 2-pyridone AMPA receptor antagonist that was recently approved as a treatment for epilepsy. The drug potently inhibits AMPA receptor responses but the mode of block has not been characterized.
Chao-Yin Chen, Lucas Matt, Johannes Wilhelm Hell, Michael A Rogawski   +3 more
doaj   +1 more source

Serum perampanel levels in patients with seizures are not affected by hemodialysis

Epilepsia Open
Perampanel belongs to a novel class of antiseizure medications (ASMs). Studies examining the effect of hemodialysis on perampanel serum levels in clinical settings are lacking.
Yusuke Nakazawa, Wataru Shiraishi, Ayano Matsuyoshi, Yukiko Inamori, Koki Mitani, Narutada Ando, Koji Shiomi, Takao Morita, Noriyuki Koga, Yuji Agawa, Takeshi Miyata, Takenori Ogura, Taketo Hatano   +12 more
doaj   +1 more source

Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina, Anna Marcé‐Grau, Barbara Masotto, Marta Codina, Lamia BenJemaa, Yasmina Elaribi, Mónica Martinez‐Gallo, Roger Colobran, Angel Sanchez‐Montañez, Irene Valenzuela, Yoshiko Murakami, Alfons Macaya   +11 more
wiley   +1 more source